Figure S15 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

<p>Resistant in parallel with parental clones of Karpas1718 cell line were exposed to a library of 348 compounds alone (single, 1µM) or in combination with 1µM idelalisib (combo) for 72h. Cell viability was measured by MTT assay (72h). Yellow for benefit in combo, purple benefit in single treatment.</p>